Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287479510> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4287479510 endingPage "13066" @default.
- W4287479510 startingPage "13059" @default.
- W4287479510 abstract "To analyze the efficacy and safety of compound Danshen dripping pills (CDDPs) in the treatment of patients with diabetic retinopathy (DR) with the syndrome of Qi stagnation and blood stasis.The clinical data of 81 patients with DR admitted to our hospital were analyzed retrospectively, and the patients were divided into an observation group (n=40) and a control group (n=41) in accordance with a random number table. The observation group was treated with CDDPs, while the control group was treated with Captopril. The response rates, change of severity degrees of retinopathy, improvement of vision, incidence of macular edema and symptom scores were compared between the two groups.(1) The ratio of decreasing degree of severity of retinopathy in the observation group was greater than that in the control group, while the ratio of increasing degree of severity of retinopathy in the observation group was lower than that in the control group (P < 0.05). There was no significant difference in the constant ratio of degree of severity of retinopathy between the two groups (P > 0.05). (2) After treatment, the scores for dim vision, somber facial complexion, dry eyes, encrusted skin and numbness of the limbs in the observation group were lower than those in the control group (P < 0.05). (3) The overall response rates (ORRs) were 87.50% and 63.41% in the observation group and the control group, respectively (P < 0.05). (4) After treatment, the vision in the left and right eye in the observation group was higher than those in the control group (P < 0.05). (5) The incidence rates of macular edema were 12.50% and 31.71% in the observation group and the control group, respectively (P < 0.05).CDDPs can effectively elevate the response rate, reduce the degree of severity of retinopathy, mitigate the incidence of macular edema, and improve the vision of DR patients with the syndrome of Qi stagnation and blood stasis, exhibiting a satisfactory safety profile. Therefore, it has a good application value." @default.
- W4287479510 created "2022-07-25" @default.
- W4287479510 creator A5057125676 @default.
- W4287479510 creator A5059211341 @default.
- W4287479510 creator A5086529957 @default.
- W4287479510 date "2021-01-01" @default.
- W4287479510 modified "2023-10-17" @default.
- W4287479510 title "Analysis of the efficacy and safety of Danshen Dripping pills on the eyes of diabetic retinopathy patients with Qi stagnation and blood stasis." @default.
- W4287479510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34956524" @default.
- W4287479510 hasPublicationYear "2021" @default.
- W4287479510 type Work @default.
- W4287479510 citedByCount "1" @default.
- W4287479510 crossrefType "journal-article" @default.
- W4287479510 hasAuthorship W4287479510A5057125676 @default.
- W4287479510 hasAuthorship W4287479510A5059211341 @default.
- W4287479510 hasAuthorship W4287479510A5086529957 @default.
- W4287479510 hasConcept C118487528 @default.
- W4287479510 hasConcept C120665830 @default.
- W4287479510 hasConcept C121332964 @default.
- W4287479510 hasConcept C134018914 @default.
- W4287479510 hasConcept C141071460 @default.
- W4287479510 hasConcept C142724271 @default.
- W4287479510 hasConcept C188947578 @default.
- W4287479510 hasConcept C204787440 @default.
- W4287479510 hasConcept C2776379591 @default.
- W4287479510 hasConcept C2778257484 @default.
- W4287479510 hasConcept C2778313320 @default.
- W4287479510 hasConcept C2779829184 @default.
- W4287479510 hasConcept C2780347916 @default.
- W4287479510 hasConcept C2780886150 @default.
- W4287479510 hasConcept C555293320 @default.
- W4287479510 hasConcept C61511704 @default.
- W4287479510 hasConcept C71924100 @default.
- W4287479510 hasConcept C81603835 @default.
- W4287479510 hasConcept C98274493 @default.
- W4287479510 hasConceptScore W4287479510C118487528 @default.
- W4287479510 hasConceptScore W4287479510C120665830 @default.
- W4287479510 hasConceptScore W4287479510C121332964 @default.
- W4287479510 hasConceptScore W4287479510C134018914 @default.
- W4287479510 hasConceptScore W4287479510C141071460 @default.
- W4287479510 hasConceptScore W4287479510C142724271 @default.
- W4287479510 hasConceptScore W4287479510C188947578 @default.
- W4287479510 hasConceptScore W4287479510C204787440 @default.
- W4287479510 hasConceptScore W4287479510C2776379591 @default.
- W4287479510 hasConceptScore W4287479510C2778257484 @default.
- W4287479510 hasConceptScore W4287479510C2778313320 @default.
- W4287479510 hasConceptScore W4287479510C2779829184 @default.
- W4287479510 hasConceptScore W4287479510C2780347916 @default.
- W4287479510 hasConceptScore W4287479510C2780886150 @default.
- W4287479510 hasConceptScore W4287479510C555293320 @default.
- W4287479510 hasConceptScore W4287479510C61511704 @default.
- W4287479510 hasConceptScore W4287479510C71924100 @default.
- W4287479510 hasConceptScore W4287479510C81603835 @default.
- W4287479510 hasConceptScore W4287479510C98274493 @default.
- W4287479510 hasIssue "11" @default.
- W4287479510 hasLocation W42874795101 @default.
- W4287479510 hasOpenAccess W4287479510 @default.
- W4287479510 hasPrimaryLocation W42874795101 @default.
- W4287479510 hasRelatedWork W12579987 @default.
- W4287479510 hasRelatedWork W14695050 @default.
- W4287479510 hasRelatedWork W15313374 @default.
- W4287479510 hasRelatedWork W17237094 @default.
- W4287479510 hasRelatedWork W21109709 @default.
- W4287479510 hasRelatedWork W4970770 @default.
- W4287479510 hasRelatedWork W7259265 @default.
- W4287479510 hasRelatedWork W8098734 @default.
- W4287479510 hasRelatedWork W8810901 @default.
- W4287479510 hasRelatedWork W4535097 @default.
- W4287479510 hasVolume "13" @default.
- W4287479510 isParatext "false" @default.
- W4287479510 isRetracted "false" @default.
- W4287479510 workType "article" @default.